To amend the Public Health Service Act to require reporting by drug manufacturers to increase transparency in drug pricing, and for other purposes.

United States115th CongressHR-4116House of Representatives
Updated: Oct 27, 2017

Summary

Transparent Drug Pricing Act of 2017 This bill requires drug manufacturers to report specified financial and sales information, including drug pricing, tax credit, and patent information; violations are subject to civil penalties.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  2. Introduced in House

  3. Referred to the Subcommittee on Health.

    House of Representatives

All available records shown.